Brought to you by 
Medivation pays $410mm up front for exclusive rights to BioMarin's PARP inhibitor
21 Jun 2019
Executive Summary
BioMarin Pharmaceutical Inc. granted Medivation Inc. exclusive global rights to its poly-ADP ribose polymerase (PARP) inhibitor talazoparib (BMN673), which is in Phase III trials for deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medivation pays $410mm up front for exclusive rights to BioMarin's PARP inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice